Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

NCT05551273 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

Hepatitis B
HIV Infections

Interventions

DRUG: Selgantolimod
DRUG: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)